Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108

TOKYO and BASKING RIDGE, N.J., Aug. 31, 2017 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo Co., Ltd. (TSE: 4568), and its U.S. subsidiary, Daiichi Sankyo, Inc. announced today that the company has elected to terminate its 2014 development an... Biopharmaceuticals Daiichi Sankyo, Charleston Laboratories, hydrocodone
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news